Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study

• Graham Cohen ,

  Roles Formal analysis, Investigation, Methodology, Validation, Writing – review & editing

  * E-mail: glcresearch@mpoc.co.za, glc@mpoc.co.za

  Affiliation Mary Potter Oncology Centre, Pretoria, South Africa

  https://orcid.org/0009-0001-4263-2693

  ⨯
• Bernardo Rapoport,

  Roles Methodology, Writing – review & editing

  Affiliations The Medical Oncology Centre of Rosebank, Johannesburg, South Africa, Department of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa

  https://orcid.org/0000-0001-7610-3653

  ⨯
• Sze W. Chan,

  Roles Investigation, Validation, Writing – review & editing

  Affiliation Sandton Oncology, Johannesburg, South Africa

  https://orcid.org/0000-0002-6174-7218

  ⨯
• Paul Ruff,

  Roles Investigation, Validation, Writing – review & editing

  Affiliation University of Witwatersrand Faculty of Health Sciences, Johannesburg, South Africa

  ⨯
• Ana Arance,

  Roles Validation, Writing – review & editing

  Affiliation Hospital Clínic de Barcelona, Barcelona, Spain

  ⨯
• Karmele Mujika Eizmendi,

  Roles Validation, Writing – review & editing

  Affiliation Onkologikoa Donostia, San Sebastian, Spain

  ⨯
• Baerin Houghton,

  Roles Investigation, Writing – review & editing

  Affiliation Port Macquarie Base Hospital, Port Macquarie, New South Wales, Australia

  ⨯
• Michael P. Brown,

  Roles Investigation, Writing – review & editing

  Affiliation Cancer Clinical Trials Unit, Royal Adelaide Hospital, and School of Medicine, The University of Adelaide, Adelaide, South Australia, Australia

  ⨯
• Robert M. Zielinski,

  Roles Validation, Writing – review & editing

  Affiliations Central West Cancer Care Centre, Orange Hospital, Orange, New South Wales, Australia, Western Sydney University, Sydney, New South Wales, Australia

  ⨯
• Eva Muñoz Couselo,

  Roles Formal analysis, Investigation, Validation, Writing – review & editing

  Affiliation Department of Medical Oncology, Melanoma and Other Skin Cancers Unit, Vall d’Hebron University Hospital, Barcelona, Spain

  ⨯
• Megan Lyle,

  Roles Investigation, Writing – review & editing

  Affiliation Liz Plummer Cancer Care Centre, Cairns, Queensland, Australia

  ⨯
• James R. Anderson,

  Roles Formal analysis, Investigation, Validation, Writing – review & editing

  Affiliation Merck & Co., Inc., Rahway, New Jersey, United States of America

  ⨯
• Lokesh Jain,

  Roles Methodology, Writing – review & editing

  Current address: Merus N.V., Cambridge, Massachusetts, United States of America

  Affiliation Merck & Co., Inc., Rahway, New Jersey, United States of America

  ⨯
• Dinesh de Alwis,

  Roles Methodology, Validation, Writing – review & editing

  Current address: Generate Biomedicines, Somerville, Massachusetts, United States of America

  Affiliation Merck & Co., Inc., Rahway, New Jersey, United States of America

  ⨯
• Mallika Lala,

  Roles Formal analysis, Investigation, Methodology, Validation, Writing – review & editing

  Affiliation Merck & Co., Inc., Rahway, New Jersey, United States of America

  ⨯
• Omobolaji Akala,

  Roles Data curation, Formal analysis, Investigation, Methodology, Validation, Writing – review & editing

  Affiliation Merck & Co., Inc., Rahway, New Jersey, United States of America

  ⨯
• Elliot Chartash,

  Roles Formal analysis, Investigation, Methodology, Validation, Writing – review & editing

  Affiliation Merck & Co., Inc., Rahway, New Jersey, United States of America

  ⨯
•  [ ... ],
• Conrad Jacobs

  Roles Validation, Writing – review & editing

  Affiliation Cancer Care: Clinical & Radiation Oncology, Cape Town, South Africa

  ⨯
• [ view all ]
• [ view less ]